Related references
Note: Only part of the references are listed.Antibody display technologies: selecting the cream of the crop
Bernhard Valldorf et al.
BIOLOGICAL CHEMISTRY (2022)
Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection
Daniel Klewinghaus et al.
FRONTIERS IN IMMUNOLOGY (2022)
Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
Yanping Li et al.
FRONTIERS IN ONCOLOGY (2022)
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
Matthias Peipp et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement
Lukas Pekar et al.
JOURNAL OF IMMUNOLOGY (2021)
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
Adeline Raynaud et al.
ONCOIMMUNOLOGY (2021)
A One-Step Process for the Construction of Phage Display scFv and VHH Libraries
Carolin Sellmann et al.
MOLECULAR BIOTECHNOLOGY (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
Lukas Pekar et al.
MABS (2020)
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Karin Staflin et al.
JCI INSIGHT (2020)
The cancer-natural killer cell immunity cycle
Nicholas D. Huntington et al.
NATURE REVIEWS CANCER (2020)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
Tugrul Elverdi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger et al.
MABS (2019)
IFN-γ: A cytokine at the right time, is in the right place
J. Daniel Burke et al.
SEMINARS IN IMMUNOLOGY (2019)
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer et al.
NEW BIOTECHNOLOGY (2019)
NK Cells in the Treatment of Hematological Malignancies
Ana P. Gonzalez-Rodriguez et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2019)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
M. Scully et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Harnessing NK Cells for Cancer Treatment
Paola Minetto et al.
FRONTIERS IN IMMUNOLOGY (2019)
Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential
Margareta P. Correia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Lionel B. Ivashkiv
NATURE REVIEWS IMMUNOLOGY (2018)
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
Sylvie Rusakiewicz et al.
ONCOIMMUNOLOGY (2017)
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy
Joachim Koch et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2017)
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
Sara Trabanelli et al.
NATURE COMMUNICATIONS (2017)
The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands
Silvia Pesce et al.
FRONTIERS IN IMMUNOLOGY (2017)
Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications
Myriam Lawand et al.
FRONTIERS IN IMMUNOLOGY (2017)
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas et al.
FRONTIERS IN IMMUNOLOGY (2017)
Camelid and shark single domain antibodies: structural features and therapeutic potential
Doreen Koenning et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
Single-domain antibodies for biomedical applications
Simon Krah et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30
Christian Kellner et al.
ONCOIMMUNOLOGY (2016)
A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma
Tong Wang et al.
CANCER LETTERS (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
Matthias Peipp et al.
ONCOTARGET (2015)
Mechanisms underlying skin disorders induced by EGFR inhibitors
Martin Holcmann et al.
MOLECULAR & CELLULAR ONCOLOGY (2015)
Therapeutic antibody engineering by high efficiency cell screening
Achim Doerner et al.
FEBS LETTERS (2014)
Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack
Wei Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity
Katrin S. Reiners et al.
BLOOD (2013)
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17
Guranda Chitadze et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Caroline Rozan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor
Mirna Balsamo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6
Yili Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
Roland Repp et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions
Sara Morgado et al.
JOURNAL OF INNATE IMMUNITY (2011)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site
M. Gordon Joyce et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells
Martin Schlaeth et al.
CANCER SCIENCE (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
CD56bright natural killer (NK) cells: an important NK cell subset
Aurelie Poli et al.
IMMUNOLOGY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
B. Grzywacz et al.
LEUKEMIA (2007)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
S Preithner et al.
MOLECULAR IMMUNOLOGY (2006)
Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma
JS Schleypen et al.
CLINICAL CANCER RESEARCH (2006)
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells
YT Bryceson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
SF Wong
CLINICAL THERAPEUTICS (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic
G Ferlazzo et al.
JOURNAL OF IMMUNOLOGY (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
